Due to the inconsistent molecular characteristics, drugs targeting molecules, including EGFR, VEGF (vascular endothelial growth factor), VEGFR, HER2, MEK, BRAF and MET, have been developed, and some of these have been approved for CRC treatment. This evidence concerns the gene MET and colorectal carcinoma.